Switch theme
Sign up to access all valuation multiples
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by China, Europe, and other regions.
2000
39.4K+
LTM Revenue $5.7B
LTM EBITDA $2.1B
$22.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Wuxi AppTec has a last 12-month revenue (LTM) of $5.7B and a last 12-month EBITDA of $2.1B.
In the most recent fiscal year, Wuxi AppTec achieved revenue of $5.4B and an EBITDA of $2.0B.
Wuxi AppTec expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Wuxi AppTec valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.7B | XXX | $5.4B | XXX | XXX | XXX |
| Gross Profit | $2.4B | XXX | $2.3B | XXX | XXX | XXX |
| Gross Margin | 42% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $2.1B | XXX | $2.0B | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 37% | XXX | XXX | XXX |
| EBIT | $1.7B | XXX | $1.6B | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $1.4B | XXX | $1.3B | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 24% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Wuxi AppTec's stock price is CNY 63 (or $9).
Wuxi AppTec has current market cap of CNY 183B (or $25.4B), and EV of CNY 164B (or $22.8B).
See Wuxi AppTec trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $22.8B | $25.4B | XXX | XXX | XXX | XXX | $0.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Wuxi AppTec has market cap of $25.4B and EV of $22.8B.
Wuxi AppTec's trades at 4.2x EV/Revenue multiple, and 11.3x EV/EBITDA.
Equity research analysts estimate Wuxi AppTec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Wuxi AppTec has a P/E ratio of 17.6x.
See valuation multiples for Wuxi AppTec and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $25.4B | XXX | $25.4B | XXX | XXX | XXX |
| EV (current) | $22.8B | XXX | $22.8B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | 11.0x | XXX | 11.3x | XXX | XXX | XXX |
| EV/EBIT | 13.4x | XXX | 14.1x | XXX | XXX | XXX |
| EV/Gross Profit | 9.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.6x | XXX | 19.4x | XXX | XXX | XXX |
| EV/FCF | 23.0x | XXX | 19.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWuxi AppTec's last 12 month revenue growth is 11%
Wuxi AppTec's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $16K for the same period.
Wuxi AppTec's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Wuxi AppTec's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Wuxi AppTec and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | 46% | XXX | 48% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $16K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wuxi AppTec acquired XXX companies to date.
Last acquisition by Wuxi AppTec was XXXXXXXX, XXXXX XXXXX XXXXXX . Wuxi AppTec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Wuxi AppTec founded? | Wuxi AppTec was founded in 2000. |
| Where is Wuxi AppTec headquartered? | Wuxi AppTec is headquartered in China. |
| How many employees does Wuxi AppTec have? | As of today, Wuxi AppTec has 39.4K+ employees. |
| Who is the CEO of Wuxi AppTec? | Wuxi AppTec's CEO is Dr. Steve Qing Yang, PhD. |
| Is Wuxi AppTec publicy listed? | Yes, Wuxi AppTec is a public company listed on SHG. |
| What is the stock symbol of Wuxi AppTec? | Wuxi AppTec trades under 603259 ticker. |
| When did Wuxi AppTec go public? | Wuxi AppTec went public in 2018. |
| Who are competitors of Wuxi AppTec? | Similar companies to Wuxi AppTec include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Wuxi AppTec? | Wuxi AppTec's current market cap is $25.4B |
| What is the current revenue of Wuxi AppTec? | Wuxi AppTec's last 12 months revenue is $5.7B. |
| What is the current revenue growth of Wuxi AppTec? | Wuxi AppTec revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Wuxi AppTec? | Current revenue multiple of Wuxi AppTec is 4.0x. |
| Is Wuxi AppTec profitable? | Yes, Wuxi AppTec is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Wuxi AppTec? | Wuxi AppTec's last 12 months EBITDA is $2.1B. |
| What is Wuxi AppTec's EBITDA margin? | Wuxi AppTec's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Wuxi AppTec? | Current EBITDA multiple of Wuxi AppTec is 11.0x. |
| What is the current FCF of Wuxi AppTec? | Wuxi AppTec's last 12 months FCF is $992M. |
| What is Wuxi AppTec's FCF margin? | Wuxi AppTec's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of Wuxi AppTec? | Current FCF multiple of Wuxi AppTec is 23.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
